Topic

Kevin A. Schug is a Full Professor and Shimadzu Distinguished Professor of Analytical Chemistry in the Department of Chemistry & Biochemistry at The University of Texas (UT) at Arlington. He joined the faculty at UT Arlington in 2005 after completing a Ph.D. in Chemistry at Virginia Tech under the direction of Prof. Harold M. McNair and a post-doctoral fellowship at the University of Vienna under Prof. Wolfgang Lindner. Research in the Schug group spans fundamental and applied areas of separation science and mass spectrometry. Schug was named the LCGC Emerging Leader in Chromatography in 2009, and most recently has been named the 2012 American Chemical Society Division of Analytical Chemistry Young Investigator in Separation Science awardee.

Articles

In April 2020, on the heels of the pandemic shutdown, the price of crude oil fell to a negative value for the first time ever. The shutdown hit many oil and gas companies hard. But while companies lick their wounds and decide their next moves, an important concept called environmental and social corporate governance (ESG) has come greater into focus.

The LCGC Blog: Environmental and Social Governance (ESG) in the Hydrocarbon Processing Industry (HPI) is an Opportunity for Industrial–Academic Partnerships

The separation science community is full of talented, productive, and innovative researchers of all genders, from diverse racial and ethnic backgrounds, working around the globe in academia and industry. Our awards should reflect this. It is one thing to say this. It is another thing to do it. But there are steps we can each take to ensure that our awards showcase the full range of separation science talent.

The LCGC Blog: Recognizing Excellence in Separation Science Wherever It’s Found

The Eastern Analytical Symposium has gone virtual for 2020, making it easy for everyone to attend. We highlight a few of the talks and innovative sessions that you won’t want to miss.

Chromatography Advances at Virtual EAS 2020

Podcasts

Current Trends in Chiral Separations

The HPLC symposium series is recognized as “the forum” where new developments in liquid phase separations and their hyphenation to mass spectrometry (MS) for the analysis of (bio)pharmaceutical compounds and their metabolites are presented.

Contemporary Trends in Biopharmaceutical Analysis

This is the second in a series of articles exploring current topics in separation science that will be addressed at the HPLC 2017 conference in Prague, Czech Republic, from 18–22 June.

HPLC 2017 Topic Preview: Contemporary Trends in Biopharmaceutical Analysis

Ion chromatography coupled to mass spectrometry (IC-MS) does not follow the same rules as coupling other modes of liquid chromatography to mass spectrometry (LC–MS). Leon Barron from the Analytical & Environmental Science Division, at King’s College London, UK, reveals some of the misconceptions surrounding IC and discusses contemporary trends and novel applications for this inventive technique.

Contemporary Trends in Ion Chromatography

In recent years, food analysis has blossomed out from a singular focus on food safety to a studies of a wide array of questions such as the authentication of food origin and the nutritional aspects of natural food compounds. In this new e-book, we explore some current trends in food analysis and also provide some concrete advice for preparing food samples for analysis.

Current Trends in Food Analysis

Leading separation scientists discuss their approaches to improving the analysis of large molecules.

Trends in Separation Science: Tackling Protein Analysis

Structural, bioanalytical, characterization, and quality control studies are critical for successful drug development. These studies must be as accurate, sensitive, and selective as possible, and liquid chromatography coupled to tandem mass spectrometry (LC–MS–MS) has been the technique of choice for many areas of small molecule analysis for the past 30 years. During that time, rapid improvements in analytical technologies have supported the development of more sensitive and robust methods. However, the pharma and biopharma industry continues to need more powerful instruments and more diverse methods, particularly as therapeutics have expanded to include large molecules. This work follows on from an earlier article that explored the limitations of LC–MS–MS for bioanalysis of biologics. This article considers some of the current issues for analysis of small and large molecules, and emerging trends in method development.

Trends | Topics